IDNA vs. HELX
Compare and contrast key facts about iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA) and Franklin Genomic Advancements ETF (HELX).
IDNA and HELX are both exchange-traded funds (ETFs), meaning they are traded on stock exchanges and can be bought and sold throughout the day. IDNA is a passively managed fund by iShares that tracks the performance of the NYSE FactSet Global Genomics and Immuno Biopharma Index. It was launched on Jun 11, 2019. HELX is an actively managed fund by Franklin Templeton. It was launched on Feb 25, 2020.
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: IDNA or HELX.
Performance
IDNA vs. HELX - Performance Comparison
Returns By Period
In the year-to-date period, IDNA achieves a 0.90% return, which is significantly higher than HELX's -6.31% return.
IDNA
0.90%
-6.10%
-4.26%
16.49%
-2.93%
N/A
HELX
-6.31%
-11.79%
-10.37%
4.57%
N/A
N/A
Key characteristics
| IDNA | HELX | |
|---|---|---|
| Sharpe Ratio | 0.97 | 0.30 |
| Sortino Ratio | 1.47 | 0.52 |
| Omega Ratio | 1.17 | 1.06 |
| Calmar Ratio | 0.34 | 0.10 |
| Martin Ratio | 4.12 | 1.15 |
| Ulcer Index | 5.22% | 4.59% |
| Daily Std Dev | 21.80% | 17.91% |
| Max Drawdown | -68.26% | -56.33% |
| Current Drawdown | -57.26% | -50.85% |
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
IDNA vs. HELX - Expense Ratio Comparison
IDNA has a 0.47% expense ratio, which is lower than HELX's 0.50% expense ratio.
Correlation
The correlation between IDNA and HELX is 0.84, which is considered to be high. That indicates a strong positive relationship between their price movements. Having highly-correlated positions in a portfolio may signal a lack of diversification, potentially leading to increased risk during market downturns.
Risk-Adjusted Performance
IDNA vs. HELX - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA) and Franklin Genomic Advancements ETF (HELX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Dividends
IDNA vs. HELX - Dividend Comparison
IDNA's dividend yield for the trailing twelve months is around 1.21%, while HELX has not paid dividends to shareholders.
| TTM | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|
IDNA iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund | 1.21% | 1.04% | 0.54% | 0.70% | 0.26% | 0.80% |
HELX Franklin Genomic Advancements ETF | 0.00% | 0.00% | 0.00% | 0.24% | 0.12% | 0.00% |
Drawdowns
IDNA vs. HELX - Drawdown Comparison
The maximum IDNA drawdown since its inception was -68.26%, which is greater than HELX's maximum drawdown of -56.33%. Use the drawdown chart below to compare losses from any high point for IDNA and HELX. For additional features, visit the drawdowns tool.
Volatility
IDNA vs. HELX - Volatility Comparison
iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA) and Franklin Genomic Advancements ETF (HELX) have volatilities of 6.93% and 6.85%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.